全文获取类型
收费全文 | 1062543篇 |
免费 | 78123篇 |
国内免费 | 13397篇 |
专业分类
耳鼻咽喉 | 14191篇 |
儿科学 | 30885篇 |
妇产科学 | 27505篇 |
基础医学 | 141441篇 |
口腔科学 | 27516篇 |
临床医学 | 94781篇 |
内科学 | 203174篇 |
皮肤病学 | 20892篇 |
神经病学 | 77819篇 |
特种医学 | 42594篇 |
外国民族医学 | 404篇 |
外科学 | 158814篇 |
综合类 | 54556篇 |
现状与发展 | 49篇 |
一般理论 | 257篇 |
预防医学 | 78519篇 |
眼科学 | 23711篇 |
药学 | 81177篇 |
192篇 | |
中国医学 | 14398篇 |
肿瘤学 | 61188篇 |
出版年
2022年 | 8202篇 |
2021年 | 13541篇 |
2020年 | 9886篇 |
2019年 | 11010篇 |
2018年 | 14109篇 |
2017年 | 12328篇 |
2016年 | 12553篇 |
2015年 | 16468篇 |
2014年 | 21808篇 |
2013年 | 29043篇 |
2012年 | 39858篇 |
2011年 | 42492篇 |
2010年 | 28123篇 |
2009年 | 25417篇 |
2008年 | 36918篇 |
2007年 | 38049篇 |
2006年 | 37583篇 |
2005年 | 35643篇 |
2004年 | 32086篇 |
2003年 | 30921篇 |
2002年 | 29544篇 |
2001年 | 44723篇 |
2000年 | 45130篇 |
1999年 | 38214篇 |
1998年 | 11108篇 |
1997年 | 10240篇 |
1996年 | 9938篇 |
1995年 | 9221篇 |
1994年 | 8675篇 |
1992年 | 28578篇 |
1991年 | 27287篇 |
1990年 | 26677篇 |
1989年 | 25556篇 |
1988年 | 23727篇 |
1987年 | 23330篇 |
1986年 | 22371篇 |
1985年 | 21248篇 |
1984年 | 15858篇 |
1983年 | 13520篇 |
1982年 | 8116篇 |
1979年 | 14628篇 |
1978年 | 10220篇 |
1977年 | 8645篇 |
1976年 | 8163篇 |
1975年 | 8968篇 |
1974年 | 10716篇 |
1973年 | 10207篇 |
1972年 | 9670篇 |
1971年 | 8925篇 |
1970年 | 8591篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
91.
目的研究腹内压升高对大鼠中心静脉压和门静脉压的影响。方法将20只成年雄性SD大鼠分别通过颈静脉插管、穿刺门静脉主干法来测定中心静脉压和门静脉压,运用氮气气腹法制作大鼠腹内高压动物模型。建立气腹后分别在0、5、10、15、20、25、30、35、40、45mmHg压力值下测得中心静脉压和门静脉压。结果中心静脉压和腹内压之间的直线回归方程为Y=2.824+0.045X,相关系数r=0.984(P〈0.01);门静脉压和腹内压之间的直线回归方程为Y=8.887+0.939X,相关系数r=0.998(P〈0.01)。结论腹内压与中心静脉压和门静脉压有很好的相关性,可以根据腹内压监测中心静脉压和门静脉压的变化。 相似文献
92.
臂丛神经卡压综合征的诊治 总被引:4,自引:0,他引:4
目的探讨位于臂丛神经及其前中斜角肌周围的神经卡压综合征的特点及其诊治方法。方法2003年7月~2006年1月,采用门诊收集病例,根据病情轻重分组,分别采用药物、局部封闭及手术方法治疗179例确诊为臂丛神经和(或)其属支卡压综合征的患者。其中采用药物、手法治疗89例;注射治疗74例,其中需要第二次注射32例;手术治疗16例,同时或分别进行双侧手术2例,需要第二次手术者1例。结果128例患者得到1个月~2年5个月随访。其中,药物手法治疗55例,症状均有不同程度改善或能维持现状。局部注射治疗58例(其中接受第二次注射者24例),2例出现心跳减缓,其余病例无并发症发生,VAS评分情况:1分2例,2分16例,3分20例,4分12例,5分3例,6分3例,7分2例;第二次注射结果:2分5例,3分16例,4分3例。手术治疗15例,其中10例术后症状得到明显改善,恢复工作。结论臂丛神经及其属支涉及其周围众多神经,可产生众多症状;明确病因后,治疗上以保守治疗为主,效果欠佳者采用手术治疗,均可取得较好疗效。 相似文献
93.
94.
95.
96.
P F Plouin D L Clement H Boccalon J Dormandy I Durand-Zaleski G Fowkes L Norgren T Brown 《International angiology》2003,22(4):333-339
Atherosclerotic renal artery stenosis (ARAS) may cause hypertension, progressive renal failure, and recurrent pulmonary edema. It typically occurs in high risk patients with coexistent vascular disease elsewhere. Most patients with ARAS are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. Recent controlled trials have shown that most patients undergoing angioplasty to treat renovascular hypertension still need antihypertensive agents 6 or 12 months after the procedure. Nevertheless, the number of antihypertensive agents required to control blood pressure adequately is lower following angioplasty than for medication alone. Trials assessing the value of revascularization for preserving renal function or preventing clinical events are only in the early recruitment phase. Revascularization should be undertaken in patients with ARAS and resistant hypertension or heart failure, and probably in those with rapidly deteriorating renal function or with an increase in plasma creatinine levels during angiotensin-converting enzyme inhibition. With or without revascularization, medical therapy using antihypertensive, hypolipidemic and antiplatelet agents is necessary in almost all cases. 相似文献
97.
Kensaku Maeda Kenichi Yasunari Eisuke F Sato Junichi Yoshikawa Masayasu Inoue 《Hypertension research》2003,26(12):999-1006
The involvement of oxidative stress in polymorphonuclear leukocytes (PMN) in the pathogenesis of hypertension remains to be elucidated. We analyzed the generation of reactive oxygen species (ROS) by the circulating and peritoneally infiltrating PMN from spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY). Flow cytometric analysis revealed that ROS generation by PMN from SHR was higher than that from WKY before (at 6 weeks of age) and after (at 16 weeks of age) the onset of hypertension. In vivo, ROS generation by PMN from SHR, but not that by PMN from WKY, was significantly suppressed by 10-week treatment with 50 mg/kg/day carvedilol, and this treatment did not affect blood pressure. Western blotting analysis revealed that protein kinase C alpha (PKCalpha), but not PKCbetaI or betaII, was activated more strongly in PMN from SHR than in PMN from WKY. Furthermore, expression of p47phox of nicotinamide adenine dinucleotide phosphate oxidase, but not of p67phox, in PMN from SHR was higher than that in PMN from WKY. These results suggest that ROS generation by PMN is principally enhanced in SHR through activation of PKCalpha and p47phox. 相似文献
98.
M. Naumann A. Albanese F. Heinen G. Molenaers M. Relja 《European journal of neurology》2006,13(S4):35-40
Botulinum toxin serotype A (BoNT-A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT-A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT-A across common therapeutic indications and showed an incidence of adverse events of approximately 25% in the BoNT-A-treated group compared with 15% in the control group. Focal weakness was the only adverse event to occur more often following BoNT-A treatment. Long-term BoNT-A administration has been assessed in various treatment settings, with the level and duration of BoNT-A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long-term, repeated, multimuscle BoNT-A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX® . These findings show long-term BoNT-A treatment to be both safe and efficacious for a wide variety of indications. 相似文献
99.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
100.